The CMT Research Foundation is pleased to announce that our partner DTx Pharma just completed the second milestone in a study we’re funding which uses their proprietary technology to suppress the overexpression of PMP22, the protein that causes CMT1A. Their work has the potential to create more potent, safer and longer-acting RNA-based therapeutics, such as … Continue reading DTx Pharma Achieves Second Milestone in Study to Advance Treatments for CMT1A